{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444509574
| ImageFile=mocetinostat.png
| ImageSize=200px
| IUPACName= ''N''-(2-Aminophenyl)-4-<nowiki>[[</nowiki>(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl] benzamide
| OtherNames=
|Section1={{Chembox Identifiers
| IUPHAR_ligand = 7008
| CASNo_Ref = {{cascite|correct|??}}
| CASNo=726169-73-9
| PubChem=9865515
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 272980
| KEGG = D09641
| SMILES=C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC3=NC=CC(=N3)C4=CN=CC=C4
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 8041206
| InChI = 1/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29)
| InChIKey = HRNLUBSXIHFDHP-UHFFFAOYAW
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = HRNLUBSXIHFDHP-UHFFFAOYSA-N
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = A6GWB8T96J

  }}
|Section2={{Chembox Properties
| C=23 | H=20 | N=6 | O=1
| Appearance=
| Density=
| MeltingPt=
| BoilingPt=
| Solubility=
  }}
|Section3={{Chembox Hazards
| MainHazards=
| FlashPt=
| AutoignitionPt =
  }}
}}

'''Mocetinostat''' ('''MGCD0103''') is a [[benzamide]] [[histone deacetylase inhibitor]] undergoing [[clinical trial]]s for treatment of various cancers including [[follicular lymphoma]], [[Hodgkin's lymphoma]] and [[Acute myeloid leukemia|acute myelogenous leukemia]].<ref>{{cite press release | url=http://www.biospace.com/news_story.aspx?NewsEntityId=20794 | deadurl=no<!--present in Internet Archive--> | title=Pharmion Corporation (PHRM) Release: Clinical Data On Oncology HDAC Inhibitor MGCD0103, Presented At The American Society of Clinical Oncology 42nd Annual Meeting | date=June 6, 2006 | publisher=BioSpace | location=Colorado, United States }}</ref><ref>{{cite conference | title=Phase I trials of the oral histone deacetylase (HDAC) inhibitor MGCD0103 given either daily or 3x weekly for 14 days every 3 weeks in patients (pts) with advanced solid tumors | author=Gelmon, K. | author2=Tolcher, A. | author3=Carducci, M. | author4=Reid, G. K. | author5=Li, Z. | author6=Kalita, A. | author7=Callejas, V. | author8=Longstreth, J. | author9=Besterman, J. M. |author10=Siu, L. L. | conference=2005 ASCO Annual Meeting. | journal=[[J. Clin. Oncol.]] | volume=23 | issue=16S | year=2005 | id=3147 | url=http://meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/3147 }}</ref><ref>[http://www.earthtimes.org/articles/show/methylgene-to-resume-development-of-its-hdac-inhibitor-mgcd0103-mocetinostat,967740.shtml MethylGene to Resume Development of its HDAC Inhibitor, MGCD0103 (Mocetinostat)], Sept 2009</ref>

One clinical trial (for refractory [[follicular lymphoma]]) was temporarily put on hold due to cardiac problems but resumed recruiting in 2009.<ref>{{cite news |url=http://www.lifescience-online.com/METHYLGENE_TO_RESUME_DEVELOPMENT_OF_ITS_HDAC_INHIB,17766.html?portalPage=Lifescience+Today.News  |title=METHYLGENE TO RESUME DEVELOPMENT OF ITS HDAC INHIBITOR, MGCD0103 (MOCETINOSTAT) |date=21 Sep 2009 }}</ref>

In 2010 favourable results were announced from the phase II trial for [[Hodgkin's lymphoma]].<ref>{{cite news |url=http://www.sys-con.com/node/1637603 |title=Final Phase 2 Clinical Data for Mocetinostat (MGCD0103) in Relapsed/Refractory Hodgkin Lymphoma Patients |date=6 Dec 2010 }}</ref>

MGCD0103 has also been used as a research reagent where blockage of members of the HDAC-family of histone deacetylases is required.<ref name=pfefferli2014>{{cite journal | title=Specific NuRD components are required for fin regeneration in zebrafish | first=Catherine | last=Pfefferli | first2=Fritz | last2=Müller | first3=Anna | last3=Jaźwińska | first4=Chantal | last4=Wicky | journal=[[BMC Biol.]] | doi=10.1186/1741-7007-12-30 | volume=12 | issue=30 | pages=30 | year=2014 | pmid=24779377 | pmc=4038851 }}{{open access}}</ref>

==Mechanism of action==
It works by inhibiting mainly histone deacetylase 1 ([[HDAC1]]), but also [[HDAC2]], [[HDAC3]], and [[HDAC11]].<ref>[http://mct.aacrjournals.org/content/7/4/759.abstract MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo]</ref>

==References==
{{Reflist}}


{{HDAC inhibitors}}

[[Category:Pyrimidines]]
[[Category:Pyridines]]
[[Category:Benzanilides]]
[[Category:Histone deacetylase inhibitors]]